Form 4: Aura Biosciences CEO Elisabet de los Pinos Executes Stock Option and Sells Shares Under 10b5-1 Plan

Elisabet de los Pinos, CEO of Aura Biosciences, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Elisabet de los Pinos, the President and CEO of Aura Biosciences, executed a transaction involving the company's stock on October 18, 2024.
• She exercised a stock option to acquire 24,992 shares at a price of $2.74 per share.
• Simultaneously, she sold 24,992 shares at a weighted average price of $12.0374, with individual sales ranging from $12.00 to $12.20.
• These transactions were conducted under a pre-existing Rule 10b5-1 trading plan established on June 22, 2023.
• Following these transactions, de los Pinos directly owns 329,847 shares and indirectly owns 131,412 shares through the Elisabet de los Pinos Revocable Trust.

Sentiment

Score: 5

Explanation: Neutral sentiment. This is a standard disclosure of insider trading activity under a pre-arranged plan, and doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. The filing itself doesn't necessarily indicate a positive or negative outlook for the company.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-arranged nature of the trades mitigates concerns about insider information being used.

Key Dates